Clinical Trials Browser

Cladribine × Clear all

NCT06463587 2026-03-19

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Phase 3 Recruiting

Myasthenia Gravis

NCT06561360 2026-03-18

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT06965114 2026-03-18

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT06021600 2026-03-09

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04375631 2026-03-05

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Phase 1 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07053020 2026-03-04

A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

Phase 1/2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04708054 2026-02-19

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

Phase 2/3 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01515527 2026-02-06

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05906914 2026-02-04

CHA

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06660368 2026-01-29

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

Phase 2 Recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03926624 2026-01-22

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Phase 3 Terminated

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07311746 2025-12-31

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

Phase 1/2 Not yet recruiting

LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

NCT05657652 2025-12-29

CAV Regimen for R/R Ph- B-ALL

Phase NA Recruiting

LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00412594 2025-12-22

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT06232655 2025-12-19

Cladribine Venetoclax in Monocytic AML

Phase 2 Recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04047641 2025-12-17

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT07032727 2025-12-15

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

Phase 2 Recruiting

Targeted Therapy

NCT03589729 2025-11-20

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Phase 2 Recruiting

MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT04797767 2025-10-15

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Phase 1/2 Recruiting

Other hematologic neoplasmSarcoma

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT02250937 2025-10-06

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06504459 2025-08-27

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

Phase 2 Active not recruiting

175 enrolled 16 charts

Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

NCT04195945 2025-07-10

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT04050280 2025-05-01

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

Phase 2 Recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05766514 2025-04-22

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Phase 2 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03150004 2025-03-26

Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Phase 2 Terminated

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06561152 2025-03-17

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06060782 2025-03-06

TCCA

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06763666 2025-01-08

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Phase 4 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02157181 2024-08-22

Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT04196010 2023-12-28

Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms

Phase 1 Terminated

Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT03531918 2023-08-30

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

Phase 1/2 Completed

66 enrolled 18 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05313958 2023-07-27

SCCLG-M5

Phase 2/3 Recruiting

Other hematologic neoplasm

Leukemia, Monocytic, Acute

NCT02728050 2023-07-05

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1/2 Completed

84 enrolled 28 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT05330377 2023-04-25

GM-CLAG in Relapsed/Refractory FLT3-mutated AML

Phase 1 Withdrawn

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT00199030 2023-03-20

Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath

Phase 2 Completed

LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT00198991 2022-08-18

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

Phase 4 Completed

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05466318 2022-07-25

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Phase 3 Unknown

Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05330364 2022-04-29

Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05053425 2022-04-26

Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML

Phase NA Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03012672 2022-03-08

Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm

Phase 2 Completed

50 enrolled 10 charts

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT00667329 2022-03-07

Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab

Phase 1 Completed

Lymphoma, Waldenstrom Macroglobulinemia

NCT02756572 2021-11-08

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Phase 2 Completed

30 enrolled 28 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03257241 2021-10-01

PALG-AML1/2016

Phase 3 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04679506 2020-12-22

the Efficacy and Safety of CLAE in R/R T-ALL/LBL

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04254640 2020-12-17

Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02921061 2020-03-17

Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS

Phase 1/2 Completed

28 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT02044796 2020-01-10

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Phase 1/2 Completed

199 enrolled 10 charts

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT00980395 2019-12-30

VCR

Phase 2 Completed

24 enrolled 11 charts

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03181815 2019-08-20

Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia

Phase 2 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute